Updated:
Keen Vision Acquisition Corp.
Kenneth Lam's Keen Vision Acquisition Corp. raised $150M in 2022 to take biotech targets public, merging with Acepodia in February 2024.
Keen Vision Acquisition Corp.
Keen Vision Acquisition Corp. was formed in 2021 by Chairman and CEO Kenneth Lam, filing with the SEC the following year to raise $150 million through an initial public offering of 15 million units. The vehicle closed in July 2022, debuting on Nasdaq under the symbol KVAC. Lam, a veteran of cross-border Asia-Pacific investment banking, assembled a board that included his son Alex Lam and CFO David Kaye, positioning the SPAC to bridge Asian innovation with U.S. public markets. The SPAC's mandate targeted biotechnology and healthcare services companies, specifically those with a nexus to Asia. Lam's sourcing network emphasized Taiwan, Hong Kong, and mainland China, where early-stage biotechs often lack clear paths to Nasdaq liquidity. In February 2024, Keen Vision announced a definitive agreement to merge with Acepodia, a clinical-stage cell therapy company based in Alameda, California, with R&D operations in Taipei (per the firm, February 2024). Acepodia's pipeline includes antibody-cell conjugation therapies for solid tumors, reflecting the precision oncology focus Lam had scoped in the original S-1. The trust raised $150 million in its IPO, with an additional over-allotment option providing flexibility during redemption windows. No concurrent PIPE was announced alongside the Acepodia de-SPAC, a structure typically sensitive to sponsor capital commitments. Lam's prior board roles at Nasdaq-listed companies including MDH Acquisition Corp. suggest a repeat-sponsor model, though Keen Vision's post-close governance details remain in proxy filings. The combined entity was expected to trade on Nasdaq post-close. The ACEPODIA transaction exemplifies a structural pattern — a U.S.-domiciled SPAC with Asian sponsor DNA targeting a biotech issuer with dual U.S.-Asia operations. This cross-border architecture differs from mainland China-backed SPACs that have faced CFIUS and audit-inspection scrutiny. Lam's regulatory path relied on Taiwanese and U.S. corporate domiciles, avoiding PCAOB-eligibility complications that stalled competing de-SPACs from mainland China targets.
General information
Firm type
other
Year founded
2021
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Summit
Corporate office
Summit, NJ, United States
Principals
Kenneth K.H. Lam
Chairman and Chief Executive Officer
Alex L.K. Lam
Director
David M. Kaye
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs Keen Vision Acquisition Corp.?
Kenneth Lam serves as Chairman and CEO. He brings a background in cross-border investment banking with a focus on Asia-Pacific capital markets. His son Alex Lam is listed as a director, and David Kaye serves as CFO. The management team reflects a family-linked governance model common among smaller SPAC sponsors.
What did Keen Vision target for its business combination?
The SPAC's mandate focused on biotechnology and healthcare services companies, particularly those with operations in Asia or an Asia-U.S. growth thesis. The S-1 highlighted a preference for businesses that could benefit from Nasdaq liquidity and U.S. investor access. The firm ultimately combined with Acepodia, a cell therapy company with clinical programs in solid tumors.
Has Keen Vision completed a de-SPAC transaction?
Yes. In February 2024, Keen Vision announced a definitive merger agreement with Acepodia, a privately held biotechnology company developing antibody-cell conjugation therapies. The transaction was structured as a standard de-SPAC with no concurrent PIPE disclosed at announcement. Post-close, the combined company was to remain Nasdaq-listed.
How is Keen Vision related to other Lam-family SPACs?
Kenneth Lam is associated with multiple SPAC vehicles. Prior to Keen Vision, he served on the board of MDH Acquisition Corp. and held roles at other blank-check entities. This repeat-sponsor model suggests a platform approach to Asia-linked U.S. listings, though Keen Vision itself was a single-purpose vehicle with no ongoing investment fund.
What differentiated Keen Vision's SPAC structure from generalist peers?
Keen Vision launched with a sector-concentrated mandate — biotechnology and healthcare — in a SPAC market dominated by generalists. Its Asia-U.S. cross-border structure avoided the PCAOB audit-inspection risks that affected SPACs targeting mainland China-based operating companies. The Acepodia combination exemplified this: a U.S.-domiciled biotech with R&D operations in Taiwan, where audit regulators faced fewer compliance barriers.
Where does Keen Vision's sponsor capital come from?
Public records do not disclose the ultimate source of sponsor capital beyond the Lam family's participation. In a typical SPAC sponsor structure, the founding team contributes at-risk capital to cover operating expenses and underwriting fees. Keen Vision's sponsor entity was likely funded by its principals, but no external LP commitments or institutional backers have been publicly identified.
Is Keen Vision still active after the Acepodia merger?
Keen Vision Acquisition Corp. was a single-purpose SPAC designed to dissolve upon completion of its initial business combination. Following the February 2024 Acepodia deal announcement, the vehicle was expected to close and delist, with Kenneth Lam transitioning to a board role at the combined company per standard de-SPAC practice. No subsequent SPAC filings from the Lam group have been publicly reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: